Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy

Clin Genitourin Cancer. 2019 Oct;17(5):e897-e902. doi: 10.1016/j.clgc.2019.06.005. Epub 2019 Jun 13.

Authors

Keitaro Watanabe¹, Takeo Kosaka², Eriko Aimono³, Hiroshi Hongo¹, Shuji Mikami⁴, Hiroshi Nishihara³, Mototsugu Oya¹

Affiliations

¹ Department of Urology, Keio University School of Medicine, Tokyo, Japan.
² Department of Urology, Keio University School of Medicine, Tokyo, Japan. Electronic address: [email protected].
³ Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
⁴ Division of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan.

PMID: 31296452
DOI: 10.1016/j.clgc.2019.06.005

No abstract available

Keywords: Enzalutamide-resistant; Neuroendocrine differentiation; Platinum-based therapy; Prostate cancer; SPOP mutation.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Allelic Imbalance
Benzamides
Carboplatin / administration & dosage*
Carboplatin / therapeutic use
Drug Resistance, Neoplasm / drug effects
Etoposide / administration & dosage*
Etoposide / therapeutic use
Humans
Japan
Male
Mutation
Nitriles
Nuclear Proteins / genetics*
Phenylthiohydantoin / analogs & derivatives
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / genetics
Repressor Proteins / genetics*
Treatment Outcome

Substances

Benzamides
Nitriles
Nuclear Proteins
Repressor Proteins
SPOP protein, human
Phenylthiohydantoin
Etoposide
enzalutamide
Carboplatin